Current Report Filing (8-k)
July 08 2019 - 4:02PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
|
July 2, 2019
|
|
Creative
Medical Technology Holdings, Inc.
|
(Exact name of registrant as specified in its charter)
|
Nevada
|
|
000-53500
|
|
88-0622284
|
(State or other jurisdiction
|
|
(Commission File Number)
|
|
(I.R.S. Employer
|
of incorporation)
|
|
|
|
Identification Number)
|
2008 W Lupine Ave, Phoenix, AZ 85029
|
(Address of principal executive offices)
|
(602) 680-7439
|
(Registrant’s telephone number, including area code)
|
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
|
Trading
Symbol(s)
|
Name of each exchange on which registered
|
N/A
|
N/A
|
N/A
|
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange
Act of 1934 (17 CFR §240.12b-2).
Emerging
growth company
¨
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
¨
|
Item 1.01.
|
Entry into a Material Definitive Agreement.
|
On July 2, 2019, Creative Medical Technology Holdings, Inc.
(the “Company”) completed the sale of 8% Original Issue Discount Senior Convertible Notes (“Notes”) and
Common Stock Purchase Warrants (“Warrants”) to two institutional investors (the “Investors”) pursuant to
a Securities Purchase Agreement between the Company and the Investors (the “Purchase Agreement”) dated as of June 28,
2019. The transaction was effected pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended and Rule 506(b) promulgated
thereunder.
Pursuant to the Purchase Agreement, for a purchase price of
$50,000.00, each Investor purchased a Note in the principal amount of $54,000.00 and a Warrant to purchase 5,555,555 shares of
common stock. Each Note matures on June 27, 2020, bears interest at a rate of 8% per annum, and is convertible into shares of the
Company’s common stock at a conversion price equal to 60% of the lowest traded price of the Company’s common stock
during the 15 trading days preceding the applicable conversion date. In addition, the Notes are subject to covenants, events of
defaults and other terms and conditions customary in transactions of this nature.
Each Warrant is exercisable for a five-year period at an initial
exercise price of $0.0045 per share, subject to anti-dilution adjustment in the event of future sales of equity by the Company
below the then exercise price, stock dividends, stock splits and other specified events.
The information set forth above is qualified in its entirety
by reference to the actual terms of the Purchase Agreement, the Notes and the Warrants, which are attached hereto as Exhibits 10.1,
4.1 and 4.2, respectively, and which are incorporated herein by reference.
|
Item 2.03.
|
Creation of a Direct Financial Obligation or an Obligation
under an Off-Balance Sheet Arrangement of a Registrant.
|
The information set forth under Item 1.01
is incorporated herein by reference.
|
Item 3.02.
|
Unregistered Sales of Equity Securities.
|
The information set forth under Item 1.01 is incorporated herein
by reference.
|
Item 9.01.
|
Financial Statements and Exhibits.
|
SIGNATURES
Pursuant to the requirements of the Securities
and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly
authorized.
|
Creative Medical Technology Holdings, Inc.
|
|
|
Date: July 8, 2019
|
By:
|
/s/ Timothy Warbington
|
|
|
Timothy Warbington, Chief Executive Officer
|